Using our extensive industry contacts, we can discuss your targeted needs, be it a product (in or out) or a company. Our network extends to both strategic sources (most focused in the bio-pharma area) as well as financial (Investment Banking, PE, and VC). Once given direction on your goals, we are able to perform an extensive search to either find the right partner(s) for your asset, or to find the type of asset you are seeking. We have worked in areas from technology platforms, early stage (PCC) products, to company acquisitions. Also notable, our network is global, covering both developed markets and emerging markets. We are glad to put our network to work for you!
We have extensive experience in complex valuations, from patient based product valuation, to company-level DCFs. When needed, we support our models with expert managed market research to validate key assumptions. Our analytics have been validated by top-tier Investment Banks, PE firms, and well know Bio-pharma companies. Our personnel have done deals that were written up in The Wall Street Journal. In addition, we have broad therapeutic area expertise, so our analysis is not just hypothetical, but based on personal market knowledge.
If requested, we can either assist with negotiations (from Term Sheets through Asset Purchase Agreements), or run them on your behalf. Our team has negotiated all types of deals, from a simple technology license to company acquisitions. No deal is too small – or too large! We’ve handled both buy-side and sell-side deals, divestitures, and of course, global deals.
We can either work with your legal counsel, or help connect you with a firm that specializes in the area in which you are interested.
While people often focus on the appeal of the negotiations, deals are usually made or broken during the diligence phase. Properly run diligence can change the value of the deal, or change the decision on whether to proceed.
On the sell side, we can help prepare and manage data rooms, and coordinate with buyers and their requests. On the buy side, we can manage the diligence process, and access subject matter experts if needed to supplement internal expertise.
It’s not just about getting a deal done, it’s about getting the right deal done!
While everyone likes to celebrate “The Signing”, not everyone realizes that the work has just begun. How will the asset transfer and be integrated into the buyer’s portfolio? Who will need to be involved in the transfer? Will there be a Transition Services Agreement? Who will manage that? Fortunately we’ve developed these plans and can either create them and give them to you, or even supply people to manage the process after it has been developed.
We can provide “End-to-End” Business Development services, from Scouting through Integration, or any individual part that you might need. While we are capable of “full service”, we are also happy to provide any of the above pieces individually.
BDMT BD (business development) advisors are a group of senior level consultants who have worked with leading biotech and pharmaceutical companies and start-ups leading critical tasks such as drug development, deal transaction, post-deal integration, etc. SSAG works with the marketing transformation specialists to meet various goals by maximizing the business opportunities for our clients.